Schedule of Accrued Expenses and Other Current Liabilities (Details) - Sonnet BioTherapeutics Holdings, Inc. [Member] - USD ($) |
Jun. 30, 2025 |
Sep. 30, 2024 |
Sep. 30, 2023 |
|---|---|---|---|
| Compensation and benefits | $ 168,281 | $ 149,802 | $ 2,091,196 |
| Research and development | 777,846 | 617,545 | 913,145 |
| Professional fees | 334,821 | 173,319 | 224,031 |
| Other | 1,958 | 1,823 | 2,550 |
| Accrued expenses and other current liabilities | $ 1,282,906 | $ 942,489 | $ 3,230,922 |
| X | ||||||||||
- Definition Accrued compensation and benefits, current. No definition available.
|
| X | ||||||||||
- Definition Accrued research and development current. No definition available.
|
| X | ||||||||||
- Definition Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer. No definition available.
|
| X | ||||||||||
- Definition Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|